Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.

Pellegrino S, Fonti R, Mazziotti E, Piccin L, Mozzillo E, Damiano V, Matano E, De Placido S, Del Vecchio S.

Ann Nucl Med. 2019 Oct 14. doi: 10.1007/s12149-019-01407-z. [Epub ahead of print]

PMID:
31612416
2.

Preclinical Imaging in Targeted Cancer Therapies.

Iommelli F, De Rosa V, Terlizzi C, Fonti R, Del Vecchio S.

Semin Nucl Med. 2019 Sep;49(5):369-381. doi: 10.1053/j.semnuclmed.2019.06.003. Epub 2019 Jun 19. Review.

PMID:
31470932
3.

PET/CT in radiation oncology.

Fonti R, Conson M, Del Vecchio S.

Semin Oncol. 2019 Jul 26. pii: S0093-7754(19)30079-X. doi: 10.1053/j.seminoncol.2019.07.001. [Epub ahead of print] Review.

PMID:
31378377
4.

Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells.

De Rosa V, Monti M, Terlizzi C, Fonti R, Del Vecchio S, Iommelli F.

Int J Mol Sci. 2019 Jun 27;20(13). pii: E3134. doi: 10.3390/ijms20133134.

5.

Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins.

Monti M, De Rosa V, Iommelli F, Carriero MV, Terlizzi C, Camerlingo R, Belli S, Fonti R, Di Minno G, Del Vecchio S.

Int J Mol Sci. 2018 Aug 9;19(8). pii: E2350. doi: 10.3390/ijms19082350.

6.

2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis.

Salvatore B, Fonti R, De Renzo A, Pellegrino S, Ferrara IL, Mainolfi CG, Marano L, Selleri C, Pane F, Del Vecchio S, Pace L.

Q J Nucl Med Mol Imaging. 2018 Apr 24. doi: 10.23736/S1824-4785.18.03043-1. [Epub ahead of print]

PMID:
29697219
7.

Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by 18F-fluorothymidine.

Iommelli F, De Rosa V, Terlizzi C, Monti M, Panico M, Fonti R, Del Vecchio S.

Clin Cancer Res. 2018 Jul 1;24(13):3126-3136. doi: 10.1158/1078-0432.CCR-17-3657. Epub 2018 Apr 4.

8.

The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.

Faggiano A, Modica R, Severino R, Camera L, Fonti R, Del Prete M, Chiofalo MG, Aria M, Ferolla P, Vitale G, Pezzullo L, Colao A.

Endocrine. 2018 Oct;62(1):46-56. doi: 10.1007/s12020-018-1583-7. Epub 2018 Mar 23.

PMID:
29572709
9.

Metastasis to the Sellar/Suprasellar Region in a Patient With Endometrial Carcinoma Detected by 18F-FDG PET/CT.

Salvatore B, D'Amico D, Fonti R.

Clin Nucl Med. 2018 May;43(5):363-364. doi: 10.1097/RLU.0000000000002037.

PMID:
29485436
10.

Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy.

Salvatore B, Klain M, Nicolai E, D'Amico D, De Matteis G, Raddi M, Fonti R, Pellegrino T, Storto G, Cuocolo A, Pace L.

Medicine (Baltimore). 2017 Oct;96(42):e8344. doi: 10.1097/MD.0000000000008344.

11.

Evaluation of metabolic response with 18F-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors.

Segreto S, Fonti R, Ottaviano M, Pellegrino S, Pace L, Damiano V, Palmieri G, Del Vecchio S.

Cancer Imaging. 2017 Mar 7;17(1):10. doi: 10.1186/s40644-017-0112-x.

12.
13.

Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.

De Luca S, Fonti R, Camera L, Salvatore B, Faggiano A, Ciarmiello A, Segreto S, Colao A, Salvatore M, Del Vecchio S.

Ann Nucl Med. 2016 Apr;30(3):234-41. doi: 10.1007/s12149-015-1056-5. Epub 2016 Jan 11.

PMID:
26753628
14.

Detection of Leptomeningeal Involvement by 18F-FDG-PET/CT in a Patient With Non-Hodgkin Lymphoma.

Fonti R, Salvatore B, De Renzo A, Nicolai E, Del Vecchio S.

Clin Nucl Med. 2016 Feb;41(2):169-72. doi: 10.1097/RLU.0000000000001060.

PMID:
26545028
15.

Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).

Lastoria S, Marciello F, Faggiano A, Aloj L, Caracò C, Aurilio M, D'Ambrosio L, Di Gennaro F, Ramundo V, Camera L, De Luca L, Fonti R, Napolitano V, Colao A.

Endocrine. 2016 Jun;52(3):488-94. doi: 10.1007/s12020-015-0702-y. Epub 2015 Aug 5.

PMID:
26242621
16.

Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer.

De Rosa V, Iommelli F, Monti M, Fonti R, Votta G, Stoppelli MP, Del Vecchio S.

Clin Cancer Res. 2015 Nov 15;21(22):5110-20. doi: 10.1158/1078-0432.CCR-15-0375. Epub 2015 Jul 27.

17.

Is 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT acquisition from the upper thigh to the vertex of skull useful in oncological patients?

Salvatore B, Caprio MG, Fonti R, D'Amico D, Fraioli F, Salvatore M, Pace L.

Transl Med UniSa. 2014 Dec 19;11:34-8. eCollection 2015 Jan-Apr.

18.

18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.

Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, Pane F, Salvatore M, Del Vecchio S.

Clin Nucl Med. 2015 Apr;40(4):303-8. doi: 10.1097/RLU.0000000000000696.

PMID:
25608167
19.

Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients.

Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, Pellegrino T, Storto G, Fonti R, Salvatore M.

Clin Nucl Med. 2015 Feb;40(2):111-5. doi: 10.1097/RLU.0000000000000621.

PMID:
25546215
20.

Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma.

Camera L, Severino R, Faggiano A, Masone S, Mansueto G, Maurea S, Fonti R, Salvatore M.

World J Radiol. 2014 Oct 28;6(10):840-5. doi: 10.4329/wjr.v6.i10.840.

21.

Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.

Iommelli F, De Rosa V, Gargiulo S, Panico M, Monti M, Greco A, Gramanzini M, Ortosecco G, Fonti R, Brunetti A, Del Vecchio S.

Clin Cancer Res. 2014 Sep 15;20(18):4806-15. doi: 10.1158/1078-0432.CCR-14-0264. Epub 2014 Jul 22.

22.

Combined imaging with 18F-FDG-PET/CT and 111In-labeled octreotide SPECT for evaluation of thymic epithelial tumors.

De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, Pace L, De Placido S, Salvatore M, Del Vecchio S.

Clin Nucl Med. 2013 May;38(5):354-8. doi: 10.1097/RLU.0b013e318286bd84.

PMID:
23486323
23.

Evidence of brown fat activity in constitutional leanness.

Pasanisi F, Pace L, Fonti R, Marra M, Sgambati D, De Caprio C, De Filippo E, Vaccaro A, Salvatore M, Contaldo F.

J Clin Endocrinol Metab. 2013 Mar;98(3):1214-8. doi: 10.1210/jc.2012-2981. Epub 2013 Feb 7.

PMID:
23393181
24.

Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.

Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, Pane F, Salvatore M, Pace L.

J Nucl Med. 2012 Dec;53(12):1829-35. doi: 10.2967/jnumed.112.106500. Epub 2012 Oct 15.

25.

Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.

Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, Faggiano A.

Clin Endocrinol (Oxf). 2013 May;78(5):760-7. doi: 10.1111/cen.12057.

PMID:
23009688
26.

PET/CT in cancer research: from preclinical to clinical applications.

Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A, Salvatore M.

Contrast Media Mol Imaging. 2010 Jul-Aug;5(4):190-200. doi: 10.1002/cmmi.368. Review.

PMID:
20812287
27.

Bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw.

Fabbricini R, Catalano L, Pace L, Del Vecchio S, Fonti R, Salvatore M, Rotoli B.

J Nucl Med. 2009 Aug;50(8):1385; author reply 1385. doi: 10.2967/jnumed.109.064568. Epub 2009 Jul 17. No abstract available.

28.

Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.

Zannetti A, Iommelli F, Fonti R, Papaccioli A, Sommella J, Lettieri A, Pirozzi G, Bianco R, Tortora G, Salvatore M, Del Vecchio S.

Clin Cancer Res. 2008 Aug 15;14(16):5209-19. doi: 10.1158/1078-0432.CCR-08-0374.

29.

18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.

Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruzziello F, Catalano L, Liuzzi R, Rotoli B, Del Vecchio S, Pace L, Salvatore M.

J Nucl Med. 2008 Feb;49(2):195-200. doi: 10.2967/jnumed.107.045641. Epub 2008 Jan 16.

30.

Functional imaging of multidrug resistance in breast cancer.

Vecchio SD, Zannetti A, Salvatore B, Paone G, Fonti R, Salvatore M.

Phys Med. 2006;21 Suppl 1:24-7.

PMID:
17645989
31.

Nuclear imaging in cancer theranostics.

Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M.

Q J Nucl Med Mol Imaging. 2007 Jun;51(2):152-63. Review.

32.

Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis.

Catalano L, Del Vecchio S, Petruzziello F, Fonti R, Salvatore B, Martorelli C, Califano C, Caparrotti G, Segreto S, Pace L, Rotoli B.

Ann Hematol. 2007 Jun;86(6):415-23. Epub 2007 Feb 7.

PMID:
17285274
33.

Washout of [99mTc] sestamibi in predicting response to chemotherapy in patients with multiple myeloma.

Pace L, Catalano L, Del Vecchio S, De Renzo A, Fonti R, Salvatore B, Andretta C, Di Nuzzo C, Rotoli B, Salvatore M.

Q J Nucl Med Mol Imaging. 2005 Sep;49(3):281-5.

34.

Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma.

Fonti R, Del Vecchio S, Zannetti A, De Renzo A, Catalano L, Pace L, Rotoli B, Salvatore M.

Cancer Biother Radiopharm. 2004 Apr;19(2):165-70.

PMID:
15186596
35.

99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients.

Andretta C, Catalano L, Pace L, Fonti R, Annunziata G, Rotoli B.

Leuk Lymphoma. 2003 Jun;44(6):1081-2. No abstract available.

PMID:
12854916
36.

New frontiers of nuclear medicine.

Salvatore M, Fonti R.

Tumori. 2002 May-Jun;88(3):S60-1. No abstract available.

PMID:
12369559
37.

Sentinel lymph node identification in breast cancer patients.

Fonti R, Limite G, Sodano A, Riccardi A, Forestieri P, De Cristofaro G, Pettinato G, Salvatore M.

Radiol Med. 2002 Apr;103(4):370-7. English, Italian.

PMID:
12107387
38.

Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients.

Del Vecchio S, Zannetti A, Ciarmiello A, Aloj L, Caracò C, Fonti R, Botti G, D'Aiuto G, Salvatore M.

Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):809-14. Epub 2002 Mar 13.

PMID:
12029556
39.

Reply.

Fonti R, Del Vecchio S, Pace L.

Eur J Nucl Med. 2001 Sep;28(9):1431-2. doi: 10.1007/s002590100577. No abstract available.

PMID:
24578057
40.

Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma.

Fonti R, Del Vecchio S, Zannetti A, De Renzo A, Di Gennaro F, Catalano L, Califano C, Pace L, Rotoli B, Salvatore M.

Eur J Nucl Med. 2001 Feb;28(2):214-20.

PMID:
11303893
41.

Lymph node mapping and sentinel lymph node biopsy for evaluation of axillary lymph node status in early invasive breast cancer. Our experience.

Formisano C, Limite G, Lamberti M, Fonti R, Forestieri P.

Przegl Lek. 2000;57 Suppl 5:113-5.

PMID:
11202270
42.

Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma.

Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M.

Cancer Res. 2000 Mar 15;60(6):1546-51.

43.

99mTc-monoclonal antibody radiolabeled via hydrazino nicotinamide derivative for imaging disialoganglioside G(D2)-positive tumors.

Fonti R, Cheung NK, Bridger GJ, Guo HF, Abrams MJ, Larson SM.

Nucl Med Biol. 1999 Aug;26(6):681-6.

PMID:
10587107
44.

Measurement of P-glycoprotein expression in human neuroblastoma xenografts using in vitro quantitative autoradiography.

Fonti R, Levchenko A, Mehta BM, Zhang J, Tsuruo T, Larson SM.

Nucl Med Biol. 1999 Jan;26(1):35-41.

PMID:
10096499
45.

Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy.

Catalano L, Pace L, Califano C, Pinto AM, De Renzo A, Di Gennaro F, Del Vecchio S, Fonti R, Salvatore M, Rotoli B.

Haematologica. 1999 Feb;84(2):119-24.

46.

Carbonic anhydrase I reduction in colonic mucosa of patients with active ulcerative colitis.

Fonti R, Latella G, Caprilli R, Frieri G, Marcheggiano A, Sambuy Y.

Dig Dis Sci. 1998 Sep;43(9):2086-92.

PMID:
9753277
47.

Measurement of P-glycoprotein expression in multidrug-resistant human neuroblastoma cell lines using self-competitive binding assay.

Levchenko A, Mehta BM, Spengler BA, Narkar AA, Fonti R, Biedler JL, Tsuruo T, Larson SM.

Anal Biochem. 1996 May 1;236(2):338-43.

PMID:
8660514
48.

Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography.

Li PY, Del Vecchio S, Fonti R, Carriero MV, Potena MI, Botti G, Miotti S, Lastoria S, Menard S, Colnaghi MI, Salvatore M.

J Nucl Med. 1996 Apr;37(4):665-72.

49.

Characterization of the mucins produced by normal human colonocytes in primary culture.

Latella G, Fonti R, Caprilli R, Marcheggiano A, Magliocca F, Das KM, Gambús G, Sambuy Y.

Int J Colorectal Dis. 1996;11(2):76-83.

PMID:
8739831
50.

In vitro receptor imaging for characterization of human solid tumors.

Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, et al.

Nucl Med Biol. 1994 Jul;21(5):771-4.

PMID:
9241653

Supplemental Content

Support Center